A PROGRAM FOR THE CURE OF TYPE 1 DIABETES USING A GENERIC DRUG: PHASE II
Researcher:
Denise L. Faustman, MD, PhD., Associate Professor
Harvard Medical School and Director Immunobiology Laboratory
Massachusetts General Hospital
Charlestown, MA
Denise L. Faustman, MD, PhD., Associate Professor
Harvard Medical School and Director Immunobiology Laboratory
Massachusetts General Hospital
Charlestown, MA
Purpose:
In August 2012, publication of the Phase I trial showed that the pancreas of long-term diabetics was able to transiently make insulin after two doses of the Bacillus Camlette-Guerin (BCG) vaccine. All Phase I clinical trial subjects who received the BCG vaccine were followed for 8 years. In 2018 a follow-up report of the 282 participants, published in the journal Vaccines, showed positive results in normalizing blood sugars after 8 years from the initial treatment with the BCG vaccine. In order to meet the goal of reversing advanced type 1 diabetes, the Phase II clinical trial was approved by the FDA in June, 2015 and that trial is now fully enrolled with 150 participants who have received at least 2 doses of the BCG vaccine or placebo. In order to meet the ultimate goal of bringing BCG to market with an approved indication for treating type 1 diabetes, it is necessary to obtain funding to
In August 2012, publication of the Phase I trial showed that the pancreas of long-term diabetics was able to transiently make insulin after two doses of the Bacillus Camlette-Guerin (BCG) vaccine. All Phase I clinical trial subjects who received the BCG vaccine were followed for 8 years. In 2018 a follow-up report of the 282 participants, published in the journal Vaccines, showed positive results in normalizing blood sugars after 8 years from the initial treatment with the BCG vaccine. In order to meet the goal of reversing advanced type 1 diabetes, the Phase II clinical trial was approved by the FDA in June, 2015 and that trial is now fully enrolled with 150 participants who have received at least 2 doses of the BCG vaccine or placebo. In order to meet the ultimate goal of bringing BCG to market with an approved indication for treating type 1 diabetes, it is necessary to obtain funding to
No comments:
Post a Comment